Nature Medicine
Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Marcilio J. Fumagalli · Anna Kaczynska · Marius Allombert · Ágata Lopes-Ribeiro · Mariângela de Oliveira Silva · Brianna J. Hernandez · Christy Lavine · Sebastian M. Espinosa · Helen Brown · Hanna Box · Emanuela Falaschetti · Louise-Rae Cherrill · Tamara Elliott · Ming Lee · Julie Fox · Sarah Pett · Amanda Clarke · Alison Uriel · Ole Sogaard · Rebecca Sutherland · Marta Boffito · Sabine Kinloch-Loes · Chloe Orkin · Simon Collins · Panagiota Zacharopoulou · Nicola Robison · Cintia Bittar · Thiago Oliveira · Anna Gazumyan · Mila Jankovic · Michael S. Seaman · John Frater · Marina Caskey · Sarah Fidler · Michel C. Nussenzweig
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04644-8In the phase 2 RIO trial, there was delayed viral rebound and resistance to broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS in adult males living with HIV undergoing analytical treatment interruption, and initial reservoir sensitivity to autologous antibodies was associated with a longer time to rebound.
15 September 2026 at 08:00

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial

By: Marcilio J. Fumagalli · Anna Kaczynska · Marius Allombert · Ágata Lopes-Ribeiro · Mariângela de Oliveira Silva · Brianna J. Hernandez · Christy Lavine · Sebastian M. Espinosa · Helen Brown · Hanna Box · Emanuela Falaschetti · Louise-Rae Cherrill · Tamara Elliott · Ming Lee · Julie Fox · Sarah Pett · Amanda Clarke · Alison Uriel · Ole Sogaard · Rebecca Sutherland · Marta Boffito · Sabine Kinloch-Loes · Chloe Orkin · Simon Collins · Panagiota Zacharopoulou · Nicola Robison · Cintia Bittar · Thiago Oliveira · Anna Gazumyan · Mila Jankovic · Michael S. Seaman · John Frater · Marina Caskey · Sarah Fidler · Michel C. Nussenzweig

15 September 2026 at 08:00

Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04644-8

In the phase 2 RIO trial, there was delayed viral rebound and resistance to broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS in adult males living with HIV undergoing analytical treatment interruption, and initial reservoir sensitivity to autologous antibodies was associated with a longer time to rebound.

Nature Medicine
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC Arsela Prelaj · Vanja Miskovic · Matteo Sacco · Alberto Ferrarin · Cristina Maria Licciardello · Leonardo Provenzano · Margherita Favali · Ludovica Lerma · Aleksandra Zec · Andrea Spagnoletti · Monica Ganzinelli · Daniele Lorenzini · Beshoy Guirges · Luca Invernizzi · Cecilia Silvestri · Laura Mazzeo · Marco Meazza Prina · Giulia Corrao · Margherita Ruggirello · Andra Diana Dumitrascu · Rosa Maria Di Mauro · Dario Monzani · Gabriella Pravettoni · Michele Zanitti · Davide Macocchi · Moreno Bruno Marino · Chiara Cavalli · Rebecca Romanò · Claudia Giani · Samuel G. Armato III · Alessandra Esposito · Christine M. Bestvina · Maria Spector · Bogot R. Naama · Reham Basheer · Adi Lahiani Hafzadi · Laila Roisman · Iris Watermann · Marlen Szewczyk · Till Olchers · Heinz Richter · Constantin Blanke-Roeser · Costanza Siniscalchi · Anna Di Lello · Teresa Arangoa · Valentina Bartolomeo · Nikolaos Spathas · Evangelos Sarris · Elena Fountzilas · Aina Arbusà Roca · Rocio Caro-Consuegra · Patricia Iranzo · Melissa Fernández-Pinto · Jose Rodríguez-Morató · Luca Agnelli · Mari
Nature Medicine, Published online: 13 September 2026; doi:10.1038/s41591-026-04488-2In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.
13 September 2026 at 08:00

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

Nature Medicine

By: Arsela Prelaj · Vanja Miskovic · Matteo Sacco · Alberto Ferrarin · Cristina Maria Licciardello · Leonardo Provenzano · Margherita Favali · Ludovica Lerma · Aleksandra Zec · Andrea Spagnoletti · Monica Ganzinelli · Daniele Lorenzini · Beshoy Guirges · Luca Invernizzi · Cecilia Silvestri · Laura Mazzeo · Marco Meazza Prina · Giulia Corrao · Margherita Ruggirello · Andra Diana Dumitrascu · Rosa Maria Di Mauro · Dario Monzani · Gabriella Pravettoni · Michele Zanitti · Davide Macocchi · Moreno Bruno Marino · Chiara Cavalli · Rebecca Romanò · Claudia Giani · Samuel G. Armato III · Alessandra Esposito · Christine M. Bestvina · Maria Spector · Bogot R. Naama · Reham Basheer · Adi Lahiani Hafzadi · Laila Roisman · Iris Watermann · Marlen Szewczyk · Till Olchers · Heinz Richter · Constantin Blanke-Roeser · Costanza Siniscalchi · Anna Di Lello · Teresa Arangoa · Valentina Bartolomeo · Nikolaos Spathas · Evangelos Sarris · Elena Fountzilas · Aina Arbusà Roca · Rocio Caro-Consuegra · Patricia Iranzo · Melissa Fernández-Pinto · Jose Rodríguez-Morató · Luca Agnelli · Mari

13 September 2026 at 08:00

Nature Medicine, Published online: 13 September 2026; doi:10.1038/s41591-026-04488-2

In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.

Nature Medicine
Strengthening clinical trial ethics and regulatory oversight in Africa: lessons from the TRACE initiative Kara L. Neil · Jeanine Condo · Obadia Kyetuza Bishoge · Peter Saula · Tendayi Kureya · Barbara E. Bierer · Willyanne DeCormier Plosky · Sarah A. White · Enock Kebenei · Beno Nyam Yakubu · Priscilla P. M. Nyambayo · Rutendo B. L. Gutsire · Sithembile Ruzario · Alphonse Ndayambaje · Nathalie Umutoni · Stella Ekallam · Ritah U. Mupende · Marie Angele Ikuzwe · Moise Ruhinda · Fantacy Twagira · Absolomon Gashaija · Vedaste Ndahindwa · Teresia Nyawira · Damas Matiko · Collins Mitambo · Elly Lefoll Kourany · David Mukanga
Nature Medicine, Published online: 07 September 2026; doi:10.1038/s41591-026-04645-7Strengthening clinical trial ethics and regulatory oversight in Africa: lessons from the TRACE initiative
7 September 2026 at 08:00

Strengthening clinical trial ethics and regulatory oversight in Africa: lessons from the TRACE initiative

Nature Medicine

7 September 2026 at 08:00

Nature Medicine, Published online: 07 September 2026; doi:10.1038/s41591-026-04645-7

Strengthening clinical trial ethics and regulatory oversight in Africa: lessons from the TRACE initiative

Nature Medicine
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial Francesca Gay · Wilfried Roeloffzen · Meletios A. Dimopoulos · Laura Rosiñol · Marjolein van der Klift · Roberto Mina · Albert Oriol · Eirini Katodritou · Ka Lung Wu · Paula Rodríguez Otero · Roman Hájek · Elisabetta Antonioli · Mark van Duin · Mattia D’Agostino · Joaquín Martínez-López · Elena M. van Leeuwen-Segarceanu · Elena Zamagni · Niels W. C. J. van de Donk · Katja C. Weisel · Luděk Pour · Jakub Radocha · Angelo Belotti · Fredrik Schjesvold · Joan Bladé · Hermann Einsele · Pieter Sonneveld · Mario Boccadoro · Annemiek Broijl
Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04282-0In the phase 3 EMN24 IsKia trial, transplant-eligible patients with newly diagnosed multiple myeloma who received isatuximab with carfilzomib, lenalidomide and dexamethasone pretransplant induction and post-transplant consolidation showed higher rates of measurable residual disease negativity after consolidation than patients who received carfilzomib, lenalidomide and dexamethasone.
6 April 2026 at 08:00

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Nature Medicine

6 April 2026 at 08:00

Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04282-0

In the phase 3 EMN24 IsKia trial, transplant-eligible patients with newly diagnosed multiple myeloma who received isatuximab with carfilzomib, lenalidomide and dexamethasone pretransplant induction and post-transplant consolidation showed higher rates of measurable residual disease negativity after consolidation than patients who received carfilzomib, lenalidomide and dexamethasone.

Nature Medicine
The exposome of brain aging across 34 countries Agustina Legaz · Sebastian Moguilner · Pablo Barttfeld · Jhosmary Cuadros Castro · Dante Sebastián Galván Rial · Joaquin Migeot · Francesca R. Farina · Raul Gonzalez-Gomez · Salomón Salazar-Londoño · Tiago de Souza Azzi · Sarael Alcauter · Lucia Amoruso · Renato Anghinah · May Bakr · María Isabel Behrens · Martin A. Bruno · Juan Felipe Cardona · Christopher Chen · Olivier Colliot · Nilton Custodio · Quentin d’Acremont · Stéphanie Debette · Patrycja Dzianok · Bahar Güntekin · Jordi Huguet · Cecilia Jarne · Marc Joliot · Elissaios Karageorgiou · Eman M. Khedr · Sheri-Michelle Koopowitz · Ewa Kublik · Jinkook Lee · Leon Aksman · Susanna Lopez · Paula Margaretic · Diana Matallana · Sophie Matis · Andreas Miltiadous · Gabriela Novotni · Patricio Orio · Mario A. Parra · Simone Reppermund · Elisa de Paula França Resende · Giovanni Abrahão Salum · Andrea Slachevsky · Ana Luisa Sosa Ortiz · Leonel Tadao Takada · An Qi Toh · Alexandros Tzallas · Wei Wen · Robert Whelan · Görsev Yener · Jonathan Adrián Zegarra Valdivia · Athanasia Alexoudi · Faheem Arshad · Ha
Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04302-zExposome analyses across 34 countries showed that social exposures were associated with faster functional brain aging and physical exposures with faster structural brain aging.
3 April 2026 at 08:00

The exposome of brain aging across 34 countries

Nature Medicine

By: Agustina Legaz · Sebastian Moguilner · Pablo Barttfeld · Jhosmary Cuadros Castro · Dante Sebastián Galván Rial · Joaquin Migeot · Francesca R. Farina · Raul Gonzalez-Gomez · Salomón Salazar-Londoño · Tiago de Souza Azzi · Sarael Alcauter · Lucia Amoruso · Renato Anghinah · May Bakr · María Isabel Behrens · Martin A. Bruno · Juan Felipe Cardona · Christopher Chen · Olivier Colliot · Nilton Custodio · Quentin d’Acremont · Stéphanie Debette · Patrycja Dzianok · Bahar Güntekin · Jordi Huguet · Cecilia Jarne · Marc Joliot · Elissaios Karageorgiou · Eman M. Khedr · Sheri-Michelle Koopowitz · Ewa Kublik · Jinkook Lee · Leon Aksman · Susanna Lopez · Paula Margaretic · Diana Matallana · Sophie Matis · Andreas Miltiadous · Gabriela Novotni · Patricio Orio · Mario A. Parra · Simone Reppermund · Elisa de Paula França Resende · Giovanni Abrahão Salum · Andrea Slachevsky · Ana Luisa Sosa Ortiz · Leonel Tadao Takada · An Qi Toh · Alexandros Tzallas · Wei Wen · Robert Whelan · Görsev Yener · Jonathan Adrián Zegarra Valdivia · Athanasia Alexoudi · Faheem Arshad · Ha

3 April 2026 at 08:00

Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04302-z

Exposome analyses across 34 countries showed that social exposures were associated with faster functional brain aging and physical exposures with faster structural brain aging.

Nature Medicine
Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancers Jeffrey van Putten · Petur Snaebjornsson · Linda J. W. Bosch · Roelof Koster · Paul Roepman · Joseph Usset · Mirjam C. Boelens · Tom van Wezel · Efraim H. Rosenberg · Serena Marchetti · Marieke Vollebergh · Doenja M. J. Lambregts · Lizet E. van der Kolk · Edwin Cuppen · Hilde H. Nienhuis · Kim Monkhorst
Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04379-6Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancers
2 April 2026 at 08:00

Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancers

Nature Medicine

By: Jeffrey van Putten · Petur Snaebjornsson · Linda J. W. Bosch · Roelof Koster · Paul Roepman · Joseph Usset · Mirjam C. Boelens · Tom van Wezel · Efraim H. Rosenberg · Serena Marchetti · Marieke Vollebergh · Doenja M. J. Lambregts · Lizet E. van der Kolk · Edwin Cuppen · Hilde H. Nienhuis · Kim Monkhorst

2 April 2026 at 08:00

Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04379-6

Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancers

Nature Medicine
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial Sebastian M. Meyhöfer · Bertrand Cariou · Cintia Cercato · Helen M. Colhoun · John Deanfield · Michelle T. Long · Ole Kleist Jeppesen · A. Michael Lincoff · Ildiko Lingvay · Jorge Plutzky · Philip N. Newsome · Stephen J. Nicholls · Maria Quiroga · Ferruccio Santini · Arun J. Sanyal · Steven E. Kahn · Donna H. Ryan · Scott S. Emerson · Robert F. Kushner · Kirstine Brown-Frandsen · G. Kees Hovingh · Søren Hardt-Lindberg · Christoffer W. Tornøe
Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04281-1A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.
2 April 2026 at 08:00

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial

Nature Medicine

2 April 2026 at 08:00

Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04281-1

A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.

Nature Medicine
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial Princess U. Ogbogu · Florence Roufosse · Praveen Akuthota · Piotr Kuna · Matthieu Groh · Andreas Reiter · Akira Yokota · Salman H. Siddiqui · Pim G. N. J. Mutsaers · Bing Li · Paneez Khoury · Lila M. Bahadori · Artur Bednarczyk · Gerben Bouma · Laura G. Brooks · Jorge Ferreira · Hanna Grindebacke · Calvin N. Ho · Priya Jain · Rebecca L. Palmer · Maria L. Jison · Amy D. Klion
Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.
31 March 2026 at 08:00

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

Nature Medicine

By: Princess U. Ogbogu · Florence Roufosse · Praveen Akuthota · Piotr Kuna · Matthieu Groh · Andreas Reiter · Akira Yokota · Salman H. Siddiqui · Pim G. N. J. Mutsaers · Bing Li · Paneez Khoury · Lila M. Bahadori · Artur Bednarczyk · Gerben Bouma · Laura G. Brooks · Jorge Ferreira · Hanna Grindebacke · Calvin N. Ho · Priya Jain · Rebecca L. Palmer · Maria L. Jison · Amy D. Klion

31 March 2026 at 08:00

Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8

Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.

Nature Medicine
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial Wungki Park · Catherine A. O’Connor · Joanne F. Chou · Marc Hilmi · Zeynep Tarcan · Carly Schwartz · Mary Larsen · Ramzi Homsi · Karthigayini Sivaprakasam · Shigeaki Umeda · Maria A. Perry · Anna M. Varghese · Kenneth H. Yu · Fiyinfolu Balogun · Alice Zervoudakis · Seth S. Katz · Tae-Hyung Kim · Ken Zhao · Allison L. Richards · Nicolas Lecomte · Daniel Martin Muldoon · Elias Karnoub · Walid Chatila · Jessica Yang · Imane El-Dika · Devika Rao · Smita Joshi · Michael B. Foote · Ryan Sugarman · James J. Harding · Andrew S. Epstein · David Kelsen · Sree Chalassani · Fergus Keane · Joshua D. Schoenfeld · Anupriya Singhal · Erin Diguglielmo · Chaitanya Bandlamudi · Junmin Song · Hulya Sahin Ozkan · Junguei Hong · Haochen Zhang · Agustin III Cardenas · Maria Lao · Jerry Melchor · Ronak Shah · Wenfei Kang · Francesca Mazzoni · Kevin Soares · Mark TA Donoghue · Ernesto Santos · Vineet Rolston · Marsha Reyngold · Alice Chia-chi Wei · Murray Tipping · Olca Basturk · Michael Berger · Richard Kihn Do · Mark Schattner · William R. Jarnagin · Nadeem Riaz · Vinod Balachandran · Dana
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.
25 March 2026 at 08:00

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Nature Medicine

By: Wungki Park · Catherine A. O’Connor · Joanne F. Chou · Marc Hilmi · Zeynep Tarcan · Carly Schwartz · Mary Larsen · Ramzi Homsi · Karthigayini Sivaprakasam · Shigeaki Umeda · Maria A. Perry · Anna M. Varghese · Kenneth H. Yu · Fiyinfolu Balogun · Alice Zervoudakis · Seth S. Katz · Tae-Hyung Kim · Ken Zhao · Allison L. Richards · Nicolas Lecomte · Daniel Martin Muldoon · Elias Karnoub · Walid Chatila · Jessica Yang · Imane El-Dika · Devika Rao · Smita Joshi · Michael B. Foote · Ryan Sugarman · James J. Harding · Andrew S. Epstein · David Kelsen · Sree Chalassani · Fergus Keane · Joshua D. Schoenfeld · Anupriya Singhal · Erin Diguglielmo · Chaitanya Bandlamudi · Junmin Song · Hulya Sahin Ozkan · Junguei Hong · Haochen Zhang · Agustin III Cardenas · Maria Lao · Jerry Melchor · Ronak Shah · Wenfei Kang · Francesca Mazzoni · Kevin Soares · Mark TA Donoghue · Ernesto Santos · Vineet Rolston · Marsha Reyngold · Alice Chia-chi Wei · Murray Tipping · Olca Basturk · Michael Berger · Richard Kihn Do · Mark Schattner · William R. Jarnagin · Nadeem Riaz · Vinod Balachandran · Dana

25 March 2026 at 08:00

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5

Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.

Nature Medicine
<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial Omar S. Mabrouk · Ben Tichler · H. Moore Arnold · Eva C. Thoma · Sara M. Alexanian · Jingxian Chen · Tzu-Ying Liu · Beth Hirschhorn · Roy Llorens Arenas · John W. Annand · Unnati Kapadnis · Alan A. Shomo · Kelly E. Glajch · Kyle Ferber · Yuka Moroishi · Julie Czerkowicz · Jennifer Inra · Ronald B. Postuma · Tanya Gurevich · Pablo Mir · Huw R. Morris · Jason Aldred · Matthew A. Brodsky · Aaron Ellenbogen · Danielle Larson · Christopher M. Tolleson · Andrew Siderowf · Charalampos Tzoulis · Ernest Balaguer · Maria J. Marti · Hien T. Zhao · Holly B. Kordasiewicz · Roger Lane · Warren D. Hirst · Stephanie Fradette · Danielle L. Graham
Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.
24 March 2026 at 08:00

<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

Nature Medicine

By: Omar S. Mabrouk · Ben Tichler · H. Moore Arnold · Eva C. Thoma · Sara M. Alexanian · Jingxian Chen · Tzu-Ying Liu · Beth Hirschhorn · Roy Llorens Arenas · John W. Annand · Unnati Kapadnis · Alan A. Shomo · Kelly E. Glajch · Kyle Ferber · Yuka Moroishi · Julie Czerkowicz · Jennifer Inra · Ronald B. Postuma · Tanya Gurevich · Pablo Mir · Huw R. Morris · Jason Aldred · Matthew A. Brodsky · Aaron Ellenbogen · Danielle Larson · Christopher M. Tolleson · Andrew Siderowf · Charalampos Tzoulis · Ernest Balaguer · Maria J. Marti · Hien T. Zhao · Holly B. Kordasiewicz · Roger Lane · Warren D. Hirst · Stephanie Fradette · Danielle L. Graham

24 March 2026 at 08:00

Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4

The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.

Nature Medicine
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial Kohei Shitara · Hirokazu Shoji · Nicola Fazio · Sara Lonardi · Keun-Wook Lee · Li-Yuan Bai · Kensei Yamaguchi · Jean-Philippe Metges · Gianluca Masi · Denis Smith · Tae-Yong Kim · Maria Matsangou · Archita Shrivastava · Miaomai Zhou · Jason Hill · Abraham Guerrero · Xuewei Wang · Aziz Zaanan · Samuel J. Klempner
Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.
16 March 2026 at 08:00

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Nature Medicine

By: Kohei Shitara · Hirokazu Shoji · Nicola Fazio · Sara Lonardi · Keun-Wook Lee · Li-Yuan Bai · Kensei Yamaguchi · Jean-Philippe Metges · Gianluca Masi · Denis Smith · Tae-Yong Kim · Maria Matsangou · Archita Shrivastava · Miaomai Zhou · Jason Hill · Abraham Guerrero · Xuewei Wang · Aziz Zaanan · Samuel J. Klempner

16 March 2026 at 08:00

Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9

In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.

Nature Medicine
A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial Aurélie Ploquin · Rosemarie D. Mason · LaSonji A. Holman · Myra Happe · Alicia T. Widge · Laura Novik · Ana M. Ortega-Villa · Galina V. Yamshchikov · Ingelise J. Gordon · Abidemi Ola · Anita Arthur · Pamela J. M. Costner · Floreliz Mendoza · Jamie Saunders · Xioalin Wang · William R. Whalen · Joanna Utoh · Jennifer Cunningham · Lorin N. Loftus · Ashley Heimann · Katia Korzeniwsky · Shayne F. Andrew · Evan Lamb · Shruthi Shyam Sunder · Amelia Thompson · Mary McDonald · Kathryn E. Foulds · Nancy J. Sullivan · Jessica Bahorich · Emily E. Coates · Rebecca J. Loomis · Barney S. Graham · Karin Bok · Sunny Himansu · Brett Leav · Walla Dempsey · John H. Beigel · Mario Roederer · Lesia K. Dropulic · Maxwell Norris · Preeti Apte · Renunda Dyer · LaShawn Requilman · Justine Jones · Larisa Strom · Tatiana Beresnev · Maryam Keshtkar-Jahromi · Caitlyn Dulan · Li Ou · I-Ting Teng · Tongqing Zhou
Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04265-1In this phase 1, open-label dose-escalation study in healthy adults found that the mRNA vaccine (mRNA-1215), encoding the Nipah virus Malaysian strain chimeric pre-fusion F protein linked to glycoprotein G, was safe and induced elevated immune responses at 1 year of follow-up, indicating that this is a promising vaccine candidate for further development.
12 March 2026 at 08:00

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial

Nature Medicine

By: Aurélie Ploquin · Rosemarie D. Mason · LaSonji A. Holman · Myra Happe · Alicia T. Widge · Laura Novik · Ana M. Ortega-Villa · Galina V. Yamshchikov · Ingelise J. Gordon · Abidemi Ola · Anita Arthur · Pamela J. M. Costner · Floreliz Mendoza · Jamie Saunders · Xioalin Wang · William R. Whalen · Joanna Utoh · Jennifer Cunningham · Lorin N. Loftus · Ashley Heimann · Katia Korzeniwsky · Shayne F. Andrew · Evan Lamb · Shruthi Shyam Sunder · Amelia Thompson · Mary McDonald · Kathryn E. Foulds · Nancy J. Sullivan · Jessica Bahorich · Emily E. Coates · Rebecca J. Loomis · Barney S. Graham · Karin Bok · Sunny Himansu · Brett Leav · Walla Dempsey · John H. Beigel · Mario Roederer · Lesia K. Dropulic · Maxwell Norris · Preeti Apte · Renunda Dyer · LaShawn Requilman · Justine Jones · Larisa Strom · Tatiana Beresnev · Maryam Keshtkar-Jahromi · Caitlyn Dulan · Li Ou · I-Ting Teng · Tongqing Zhou

12 March 2026 at 08:00

Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04265-1

In this phase 1, open-label dose-escalation study in healthy adults found that the mRNA vaccine (mRNA-1215), encoding the Nipah virus Malaysian strain chimeric pre-fusion F protein linked to glycoprotein G, was safe and induced elevated immune responses at 1 year of follow-up, indicating that this is a promising vaccine candidate for further development.

Nature Medicine
A cognitive layer architecture to support large-language model performance in psychotherapy interactions Max Rollwage · Jessica McFadyen · Keno Juchems · Annamaria Balogh · Sashank Pisupati · Margareta-Theodora Mircea · Tobias U. Hauser · George Prichard · Ross Harper
Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04278-wA real-world study showed that introducing a cognitive layer architecture to support specialized psychotherapeutic reasoning capabilities in general-purpose chatbots improved depression and anxiety symptoms compared to chatbots or therapists alone.
12 March 2026 at 08:00

A cognitive layer architecture to support large-language model performance in psychotherapy interactions

Nature Medicine

By: Max Rollwage · Jessica McFadyen · Keno Juchems · Annamaria Balogh · Sashank Pisupati · Margareta-Theodora Mircea · Tobias U. Hauser · George Prichard · Ross Harper

12 March 2026 at 08:00

Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04278-w

A real-world study showed that introducing a cognitive layer architecture to support specialized psychotherapeutic reasoning capabilities in general-purpose chatbots improved depression and anxiety symptoms compared to chatbots or therapists alone.

Nature Medicine
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis Stephan A. Kaeser · Stephanie A. Schultz · Anna Hofmann · Lisa M. Häsler · Ying Xu · Marius Lambert · Ulrike Obermüller · Kathrin Brockmann · Johan Bijzet · Hans Nienhuis · Mario Nuvolone · Laura Obici · Giovanni Palladini · Ute Hegenbart · Stefan O. Schönland · Mathias Jucker
Nature Medicine, Published online: 11 March 2026; doi:10.1038/s41591-026-04272-2Elevated serum levels of phosphorylated tau are not specific to Alzheimer’s disease and may also serve as a diagnostic tool for the most common types of systemic amyloidosis, with potential utility in distinguishing amyloidosis-related polyneuropathy from polyneuropathy of other etiologies.
11 March 2026 at 08:00

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis

Nature Medicine

By: Stephan A. Kaeser · Stephanie A. Schultz · Anna Hofmann · Lisa M. Häsler · Ying Xu · Marius Lambert · Ulrike Obermüller · Kathrin Brockmann · Johan Bijzet · Hans Nienhuis · Mario Nuvolone · Laura Obici · Giovanni Palladini · Ute Hegenbart · Stefan O. Schönland · Mathias Jucker

11 March 2026 at 08:00

Nature Medicine, Published online: 11 March 2026; doi:10.1038/s41591-026-04272-2

Elevated serum levels of phosphorylated tau are not specific to Alzheimer’s disease and may also serve as a diagnostic tool for the most common types of systemic amyloidosis, with potential utility in distinguishing amyloidosis-related polyneuropathy from polyneuropathy of other etiologies.

Normal view